Mumbai: Sun Pharmaceutical Industries on Thursday said it has got tentative approval from the US drug regulator for its generic product Strattera used in the treatment of mental disorders.
The US Food and Drug Administration has approved Strattera
atomoxetine hydrochloride capsules, which is equivalent to
drug manufacturer Eli Lilly`s Strattera capsules, Sun Pharma
said in a filing to the Bombay Stock Exchange (BSE).
These capsules are available in seven strengths--10 mg,
18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the Mumbai-based
drug maker said.
The capsules, used in the treatment of attention deficit
hyperactivity disorder, have an annual sales of nearly USD 500
million in the US.
Shares of Sun Pharma today closed at Rs 1463.25, higher
by 0.78 per cent from its previous close on the BSE, whose
benchmark index--Sensex--fell by 344.02 points to close at